Pediatric patients with atopic dermatitis (AD) often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, said Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.
Pediatric patients with atopic dermatitis often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, according to Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and vice-chair and professor of dermatology and pediatrics at UC San Diego School of Medicine.
Transcript
How does treating pediatric patients with atopic dermatitis differ from treating adult patients?
Eichenfield: In any patient with atopic dermatitis, we're assessing the severity of the disease and also the course of the disease, the persistence. In pediatric atopic dermatitis, we have this tremendous variation, from young infants who might have disease that's easy to get under control, with traditional mild topical corticosteroids and they just need moisturizers in between, to more severe diseases. But as we go on in an age to the older children and teens, there's always issues in terms of what's an appropriate amount of topical therapy to control disease and keep it under control. It's a lot of work, with different topical agents. We have both our steroids and nonsteroids. We have to work with the families to understand what's a safe amount of medicine to use and to determine if we need something beyond topical medicines to keep the disease under control.
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More